Could a new pill stop lung scarring from getting worse?
NCT ID NCT06714123
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 28 times
Summary
This study tests a drug called senicapoc to see if it can prevent lung scarring from getting worse in people with progressive fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 adults will take either senicapoc or a placebo for 26 weeks. Researchers will measure lung function, track side effects, and follow participants for a total of 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus N, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Odense University Hospital
NOT_YET_RECRUITINGOdense C, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tartu University Hospital,
NOT_YET_RECRUITINGTartu, 50406, Estonia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.